Boenning & Scattergood Initiates Coverage on DexCom (DXCM) with an Outperform
More News related to DXCM
- DexCom To Present at the Piper Jaffray 21st Annual Health Care Conference
- DexCom Appoints Nicholas Augustinos as Board Member
- DexCom To Present at Lazard Capital Markets 6th Annual Healthcare Conference
- DexCom (DXCM) Posts Q3 Loss of 29c, Beats by 3c
- DexCom Inc. Reports Third Quarter 2009 Financial Results
Boenning & Scattergood initiates coverage on DexCom (Nasdaq: DXCM) with an Outperform rating. Price target $9.
To see more analyst ratings on DXCM Click Here.
DexCom, Inc., a medical device company, engages in the design, development, and commercialization of continuous glucose monitoring systems for people with diabetes in the United States.
Related Categories
New CoverageStocks Mentioned
-0.27Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
